Inflammation as a central mechanism in Alzheimer's disease Tập 4 Số 1 - Trang 575-590 - 2018
Jefferson W. Kinney, Shane M. Bemiller, Andrew S. Murtishaw, Amanda M. Leisgang, Arnold Salazar, Bruce T. Lamb
AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder
that is characterized by cognitive decline and the presence of two core
pathologies, amyloid β plaques and neurofibrillary tangles. Over the last
decade, the presence of a sustained immune response in the brain has emerged as
a third core pathology in AD. The sustained activation of the brain's resident
macrophages (micro... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2018 Tập 4 Số 1 - Trang 195-214 - 2018
Jeffrey L. Cummings, Garam Lee, Aaron Ritter, Kate Zhong
AbstractIntroductionTreatments for Alzheimer's disease (AD) are needed due to
the growing number of individuals with preclinical, prodromal, and dementia
forms of AD. Drug development for AD therapies can be examined by inspecting the
drug development pipeline as represented on
clinicaltrials.gov.MethodsClinicaltrials.gov was assessed as of January 30, 2018
to determine AD therapies represented in... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2017 Tập 3 Số 3 - Trang 367-384 - 2017
Jeffrey L. Cummings, Garam Lee, Travis Mortsdorf, Aaron Ritter, Kate Zhong
AbstractIntroductionThere is an urgent need to develop new treatments for
Alzheimer's disease (AD) and to understand the drug development process for new
AD therapies.MethodsWe assessed the agents in the AD pipeline as documented in
clinicaltrials.gov for phase I, phase II, and phase III, accessed
1/5/2017.ResultsThere are 105 agents in the AD treatment development pipeline,
of which 25 agents are... hiện toàn bộ
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health Tập 3 Số 3 - Trang 291-300 - 2017
Michael J. Wheeler, Paddy C. Dempsey, Megan S. Grace, Kathryn A. Ellis, Paul A. Gardiner, Daniel J. Green, David W. Dunstan
AbstractCognitive decline leading to dementia represents a global health burden.
In the absence of targeted pharmacotherapy, lifestyle approaches remain the best
option for slowing the onset of dementia. However, older adults spend very
little time doing moderate to vigorous exercise and spend a majority of time in
sedentary behavior. Sedentary behavior has been linked to poor glycemic control
and... hiện toàn bộ
Accelerating drug development for Alzheimer's disease through the use of data standards Tập 3 - Trang 273-283 - 2017
Jon Neville, Steve Kopko, Klaus Romero, Brian Corrigan, Bob Stafford, Elizabeth LeRoy, Steve Broadbent, Martin Cisneroz, Ethan Wilson, Eric Reiman, Hugo Vanderstichele, Stephen P. Arnerić, Diane Stephenson
AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's
disease (AD) calls for immediate attention to improve efficiencies and learning
from past, ongoing, and future trials. Accurate, highly rigorous standardized
data are at the core of meaningful scientific research. Data standards allow for
proper integration of clinical data sets and represent the essential foundation
for... hiện toàn bộ
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints Tập 4 - Trang 444-449 - 2018
Rebecca E. Amariglio, Rachel F. Buckley, Elizabeth C. Mormino, Gad A. Marshall, Keith A. Johnson, Dorene M. Rentz, Reisa A. Sperling
AbstractIntroductionTo investigate whether baseline subjective cognitive
complaints (SCCs) predict longitudinal decline on neuropsychological testing and
whether SCC increases longitudinally, in the setting of high levels of amyloid
burden.MethodsTwo hundred seventy‐nine clinically normal older participants
(mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of
community‐dwe... hiện toàn bộ
Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial Tập 4 - Trang 499-507 - 2018
Jennifer A. Deal, Adele M. Goman, Marilyn S. Albert, Michelle L. Arnold, Sheila Burgard, Theresa Chisolm, David Couper, Nancy W. Glynn, Theresa Gmelin, Kathleen M. Hayden, Thomas Mosley, James S. Pankow, Nicholas Reed, Victoria A. Sanchez, A. Richey Sharrett, Sonia D. Thomas, Josef Coresh, Frank R. Lin
AbstractIntroductionHearing impairment is highly prevalent and independently
associated with cognitive decline. The Aging and Cognitive Health Evaluation in
Elders study is a multicenter randomized controlled trial to determine efficacy
of hearing treatment in reducing cognitive decline in older adults.
Clinicaltrials.gov Identifier: NCT03243422.MethodsEight hundred fifty
participants without deme... hiện toàn bộ
Proof of concept demonstration of optimal composite MRI endpoints for clinical trials Tập 2 - Trang 177-181 - 2016
Steven D. Edland, M. Colin Ard, Jaiashre Sridhar, Derin Cobia, Adam Martersteck, M.-Marsel Mesulam, Emily J. Rogalski
AbstractIntroductionAtrophy measures derived from structural MRI are promising
outcome measures for early phase clinical trials, especially for rare diseases
such as primary progressive aphasia (PPA), where the small available subject
pool limits our ability to perform meaningfully powered trials with traditional
cognitive and functional outcome measures.MethodsWe investigated a composite
atrophy ... hiện toàn bộ
Reconsidering frameworks of Alzheimer's dementia when assessing psychosocial outcomes Tập 5 - Trang 388-397 - 2019
Joseph E. Gaugler, Lisa J. Bain, Lauren Mitchell, Jessica Finlay, Sam Fazio, Eric Jutkowitz
AbstractThe purpose of this introductory article to the special issue on
psychosocial outcome measures in Alzheimer's & Dementia: Translational Research
& Clinical Interventions is to outline new frameworks to more effectively
capture and measure the full range of how people living with Alzheimer's
dementia and their family caregivers experience the disease process.
Specifically, we consider the s... hiện toàn bộ
Insufficient evidence for vitamin E in Alzheimer's disease Tập 2 - Trang 199-201 - 2016
Dirk M. Hermann
AbstractVitamin E has recently been suggested to slow down the progression of
Alzheimer's disease. Current evidence is based on three studies in patients with
Alzheimer's disease and one study in patients with mild cognitive impairment
which all together included only 1756 patients. Importantly, two of these
studies were negative, and the two other studies had severe methodological
weaknesses that... hiện toàn bộ